646 related articles for article (PubMed ID: 33296242)
1. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Richardson PG; Oriol A; Larocca A; Bladé J; Cavo M; Rodriguez-Otero P; Leleu X; Nadeem O; Hiemenz JW; Hassoun H; Touzeau C; Alegre A; Paner A; Maisel C; Mazumder A; Raptis A; Moreb JS; Anderson KC; Laubach JP; Thuresson S; Thuresson M; Byrne C; Harmenberg J; Bakker NA; Mateos MV;
J Clin Oncol; 2021 Mar; 39(7):757-767. PubMed ID: 33296242
[TBL] [Abstract][Full Text] [Related]
2. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
Richardson PG; Bringhen S; Voorhees P; Plesner T; Mellqvist UH; Reeves B; Paba-Prada C; Zubair H; Byrne C; Chauhan D; Anderson K; Nordström E; Harmenberg J; Palumbo A; Sonneveld P
Lancet Haematol; 2020 May; 7(5):e395-e407. PubMed ID: 32213344
[TBL] [Abstract][Full Text] [Related]
3. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Schjesvold FH; Dimopoulos MA; Delimpasi S; Robak P; Coriu D; Legiec W; Pour L; Špička I; Masszi T; Doronin V; Minarik J; Salogub G; Alekseeva Y; Lazzaro A; Maisnar V; Mikala G; Rosiñol L; Liberati AM; Symeonidis A; Moody V; Thuresson M; Byrne C; Harmenberg J; Bakker NA; Hájek R; Mateos MV; Richardson PG; Sonneveld P;
Lancet Haematol; 2022 Feb; 9(2):e98-e110. PubMed ID: 35032434
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study.
Pour L; Szarejko M; Bila J; Schjesvold FH; Spicka I; Maisnar V; Jurczyszyn A; Grudeva-Popova Z; Hájek R; Usenko G; Thuresson M; Norin S; Jarefors S; Bakker NA; Richardson PG; Mateos MV
Haematologica; 2024 Mar; 109(3):895-905. PubMed ID: 37646660
[TBL] [Abstract][Full Text] [Related]
5. Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1.
Bringhen S; Voorhees PM; Plesner T; Mellqvist UH; Reeves B; Sonneveld P; Byrne C; Nordström E; Harmenberg J; Obermüller J; Richardson PG
Br J Haematol; 2021 Jun; 193(6):1105-1109. PubMed ID: 33403663
[TBL] [Abstract][Full Text] [Related]
6. Melflufen for relapsed and refractory multiple myeloma.
Oriol A; Larocca A; Leleu X; Hajek R; Hassoun H; Rodríguez-Otero P; Paner A; Schjesvold FH; Gullbo J; Richardson PG
Expert Opin Investig Drugs; 2020 Oct; 29(10):1069-1078. PubMed ID: 32924646
[TBL] [Abstract][Full Text] [Related]
7. OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma.
Schjesvold F; Robak P; Pour L; Aschan J; Sonneveld P
Future Oncol; 2020 Apr; 16(11):631-641. PubMed ID: 32141766
[TBL] [Abstract][Full Text] [Related]
8. ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.
Ocio EM; Efebera YA; Hájek R; Straub J; Maisnar V; Eveillard JR; Karlin L; Mateos MV; Oriol A; Ribrag V; Richardson PG; Norin S; Obermüller J; Bakker NA; Pour L
Haematologica; 2024 Mar; 109(3):867-876. PubMed ID: 37646657
[TBL] [Abstract][Full Text] [Related]
9. Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study.
Schjesvold FH; Ludwig H; Mateos MV; Larocca A; Abdulhaq H; Norin S; Thuresson M; Bakker NA; Richardson PG; Sonneveld P
Eur J Haematol; 2024 Mar; 112(3):402-411. PubMed ID: 37968873
[TBL] [Abstract][Full Text] [Related]
10. Pepaxto: A New Peptide-Drug Conjugate for Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Jessee JK
Ann Pharmacother; 2022 Aug; 56(8):951-957. PubMed ID: 34963319
[TBL] [Abstract][Full Text] [Related]
11. Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma.
Morabito F; Tripepi G; Martino EA; Vigna E; Mendicino F; Morabito L; Todoerti K; Al-Janazreh H; D'Arrigo G; Canale FA; Cutrona G; Neri A; Martino M; Gentile M
Drug Des Devel Ther; 2021; 15():2969-2978. PubMed ID: 34262262
[TBL] [Abstract][Full Text] [Related]
12. Melflufen for the treatment of multiple myeloma.
Ocio EM; Nadeem O; Schjesvold F; Gay F; Touzeau C; Dimopoulos MA; Richardson PG; Mateos MV
Expert Rev Clin Pharmacol; 2022 Apr; 15(4):371-382. PubMed ID: 35723075
[TBL] [Abstract][Full Text] [Related]
13. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
[TBL] [Abstract][Full Text] [Related]
14. Melphalan flufenamide for relapsed/refractory multiple myeloma.
Nadeem O; Mateos MV; Efebera YA; Paner A; Larocca A; Rodríguez-Otero P; Leleu X; Richardson PG
Drugs Today (Barc); 2022 Aug; 58(8):407-423. PubMed ID: 35983927
[TBL] [Abstract][Full Text] [Related]
15. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Mikhael J; Richardson P; Usmani SZ; Raje N; Bensinger W; Karanes C; Campana F; Kanagavel D; Dubin F; Liu Q; Semiond D; Anderson K
Blood; 2019 Jul; 134(2):123-133. PubMed ID: 30862646
[TBL] [Abstract][Full Text] [Related]
16. Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies.
Sonneveld P; Richardson PG; Ludwig H; Dimopoulos MA; Schjesvold FH; Hájek R; Abdulhaq H; Thuresson M; Norin S; Bakker NA; Mateos MV
Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):687-696. PubMed ID: 37355418
[TBL] [Abstract][Full Text] [Related]
17. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
[TBL] [Abstract][Full Text] [Related]
18. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.
Larocca A; Leleu X; Touzeau C; Bladé J; Paner A; Mateos MV; Cavo M; Maisel C; Alegre A; Oriol A; Raptis A; Rodriguez-Otero P; Mazumder A; Laubach J; Nadeem O; Sandberg A; Orre M; Torrång A; Bakker NA; Richardson PG
Br J Haematol; 2022 Feb; 196(3):639-648. PubMed ID: 34671975
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
Dimopoulos MA; Hungria VTM; Radinoff A; Delimpasi S; Mikala G; Masszi T; Li J; Capra M; Maiolino A; Pappa V; Chraniuk D; Osipov I; Leleu X; Low M; Matsumoto M; Sule N; Li M; McKeown A; He W; Bright S; Currie B; Perera S; Boyle J; Roy-Ghanta S; Opalinska J; Weisel K
Lancet Haematol; 2023 Oct; 10(10):e801-e812. PubMed ID: 37793771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
